Method to measure the mismatch between target and achieved received dose intensity of chemotherapy in cancer trials: a retrospective analysis of the MRC BO06 trial in osteosarcoma

OBJECTIVES: In cancer studies, the target received dose intensity (tRDI) for any regimen, the intended dose and time for the regimen, is commonly taken as a proxy for achieved RDI (aRDI), the actual individual dose and time for the regimen. Evaluating tRDI/aRDI mismatches is crucial to assess study...

Descripción completa

Detalles Bibliográficos
Autores principales: Lancia, Carlo, Anninga, Jakob, Spitoni, Cristian, Sydes, Matthew R., Whelan, Jeremy, Hogendoorn, Pancras C W, Gelderblom, Hans, Fiocco, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549670/
https://www.ncbi.nlm.nih.gov/pubmed/31152023
http://dx.doi.org/10.1136/bmjopen-2018-022980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549670/
https://www.ncbi.nlm.nih.gov/pubmed/31152023
http://dx.doi.org/10.1136/bmjopen-2018-022980

Ejemplares similares